{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:53:06Z","timestamp":1781502786960,"version":"3.54.1"},"reference-count":79,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This review reflects the presentations and discussion at the 14th post\u2010American Society of Hematology (ASH) International Workshop on Chronic Myeloproliferative Malignancies, which took place on the December 10 and 11, 2019, immediately after the 61st ASH Annual Meeting in Orlando, Florida. Rather than present a resume of the proceedings, we address some of the topical translational science research and clinically relevant topics in detail. We consider how recent studies using single\u2010cell genomics and other molecular methods reveal novel aspects of hematopoiesis which in turn raise the possibility of new therapeutic approaches for patients with myeloproliferative neoplasms (MPNs). We discuss how alternative therapies could benefit patients with chronic myeloid leukemia who develop\n                    <jats:italic>BCR\u2010ABL<\/jats:italic>\n                    1 mutant subclones following\n                    <jats:italic>ABL<\/jats:italic>\n                    1\u2010tyrosine kinase inhibitor therapy. In MPNs, we focus on efforts beyond JAK\u2010STAT and the merits of integrating activin receptor ligand traps, interferon\u2010\u03b1, and allografting in the current treatment algorithm for patients with myelofibrosis.\n                  <\/jats:p>","DOI":"10.1002\/hon.2771","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T07:50:02Z","timestamp":1593244202000},"page":"654-664","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1005-7724","authenticated-orcid":false,"given":"Tariq I.","family":"Mughal","sequence":"first","affiliation":[{"name":"Tufts University Medical Center  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethan","family":"Psaila","sequence":"additional","affiliation":[{"name":"MRC Weatherall Institute of Molecular Medicine University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[{"name":"Frederick Hutchinson Cancer Research Center  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lion","sequence":"additional","affiliation":[{"name":"Childrens Cancer Research Institute  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Jacques","family":"Kiladjian","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint\u2010Louis, Universit\u00e9 de Paris  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit","family":"Rampal","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Cancer Center, John Hopkins Hospital  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdnan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies University of Kansas  Kansas City Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University  Augusta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"Mays Cancer Center at UT Health San Antonio MD Anderson  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"Orbassano University Hospital  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"van Etten","sequence":"additional","affiliation":[{"name":"University of California Irvine  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139337"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2622"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1315"},{"issue":"1","key":"e_1_2_12_5_1","first-page":"1","article-title":"Single\u2010cell multimodal omics","volume":"17","author":"Method of the Year 2019","year":"2020","journal-title":"Nat Methods"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-018-0227-8"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-835371"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000613"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.01.009"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.04.040"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201848053"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1104-8"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10291-0"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.04.008"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12943"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.176347"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.11.004"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3468"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-876888"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12838"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001057"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2018-99-110805","article-title":"The medalist trial: results of a phase 3, randomized, double\u2010blind, placebo\u2010controlled study of luspatercept to treat anemia in patients with very low\u2010, low\u2010, or intermediate\u2010risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions","volume":"132","author":"Fenaux P","year":"2018","journal-title":"Blood"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2012.12.002"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488098"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000561596.81498.79"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.07.015"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122546"},{"key":"e_1_2_12_28_1","first-page":"5","article-title":"Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF\u2010beta","volume":"3","author":"Agarwal A","year":"2016","journal-title":"Stem Cell Investig"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-783225"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3194-4"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15061"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123775"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"issue":"1","key":"e_1_2_12_37_1","first-page":"4197","article-title":"Case series of potential Wernicke's encephalopathy in patients treated with fedratinib","volume":"130","author":"Harrison CN","year":"2017","journal-title":"Blood"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16573"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16576BJH"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-019-0166-y"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310523"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.06.006"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00538-4"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130158"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127119"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127859"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127661"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7058"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123244"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116474"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815105"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129397"},{"issue":"1","key":"e_1_2_12_58_1","first-page":"655","article-title":"Final results of phase 2 clinical trial of LCVL161, a novel oral SMAC mimetic\/IAP anatagonist, for patients with intermediate to high risk myelofibrosis","volume":"134","author":"Pemmaraju N","year":"2019","journal-title":"Blood"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130648"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205211"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0226-1"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.323"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.3.1013.1013"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9867"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.169"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0107-z"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0302-9"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018026658"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-890889"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.01.002"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30030-3"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000428"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124865"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30236-4"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122233"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-03-900860"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2771","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2771","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2771","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:11:26Z","timestamp":1781500286000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1002\/hon.2771"],"URL":"https:\/\/doi.org\/10.1002\/hon.2771","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"2020-06-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}